Epstein Files Full PDF

CLICK HERE
Technopedia Center
PMB University Brochure
Faculty of Engineering and Computer Science
S1 Informatics S1 Information Systems S1 Information Technology S1 Computer Engineering S1 Electrical Engineering S1 Civil Engineering

faculty of Economics and Business
S1 Management S1 Accountancy

Faculty of Letters and Educational Sciences
S1 English literature S1 English language education S1 Mathematics education S1 Sports Education
teknopedia

  • Registerasi
  • Brosur UTI
  • Kip Scholarship Information
  • Performance
Flag Counter
  1. World Encyclopedia
  2. Bone morphogenetic protein 8A - Wikipedia
Bone morphogenetic protein 8A - Wikipedia
From Wikipedia, the free encyclopedia
(Redirected from BMP8A)

Protein-coding gene in the species Homo sapiens
BMP8A
Identifiers
AliasesBMP8A, entrez:353500, bone morphogenetic protein 8a, OP-2
External IDsMGI: 104515; HomoloGene: 135983; GeneCards: BMP8A; OMA:BMP8A - orthologs
Gene location (Human)
Chromosome 1 (human)
Chr.Chromosome 1 (human)[1]
Chromosome 1 (human)
Genomic location for BMP8A
Genomic location for BMP8A
Band1p34.3Start39,491,636 bp[1]
End39,529,869 bp[1]
Gene location (Mouse)
Chromosome 4 (mouse)
Chr.Chromosome 4 (mouse)[2]
Chromosome 4 (mouse)
Genomic location for BMP8A
Genomic location for BMP8A
Band4 D2.2|4 57.42 cMStart123,206,438 bp[2]
End123,237,045 bp[2]
RNA expression pattern
Bgee
HumanMouse (ortholog)
Top expressed in
  • right lobe of thyroid gland

  • left lobe of thyroid gland

  • periodontal fiber

  • tibia

  • C1 segment

  • left ovary

  • right ovary

  • islet of Langerhans

  • smooth muscle tissue

  • tibial nerve
Top expressed in
  • decidua

  • gastrula

  • intestinal villus

  • calvaria

  • hair follicle

  • molar

  • jejunum

  • embryo

  • Ileal epithelium

  • body of femur
More reference expression data
BioGPS
n/a
Gene ontology
Molecular function
  • transforming growth factor beta receptor binding
  • cytokine activity
  • BMP receptor binding
  • growth factor activity
Cellular component
  • extracellular region
  • extracellular space
Biological process
  • regulation of apoptotic process
  • multicellular organism development
  • positive regulation of pathway-restricted SMAD protein phosphorylation
  • cartilage development
  • negative regulation of insulin secretion
  • cell differentiation
  • regulation of MAPK cascade
  • SMAD protein signal transduction
  • cell development
  • BMP signaling pathway
  • ossification
  • diet induced thermogenesis
  • regulation of signaling receptor activity
  • energy homeostasis
Sources:Amigo / QuickGO
Orthologs
SpeciesHumanMouse
Entrez

353500

12163

Ensembl

ENSG00000183682

ENSMUSG00000032726

UniProt

Q7Z5Y6

P34821

RefSeq (mRNA)

NM_181809

NM_001256019
NM_007558

RefSeq (protein)

NP_861525

NP_001242948
NP_031584

Location (UCSC)Chr 1: 39.49 – 39.53 MbChr 4: 123.21 – 123.24 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Bone morphogenetic protein 8A (BMP8A) is a protein that in humans is encoded by the BMP8A gene.[5]

BMP8A is a polypeptide member of the TGFβ superfamily of proteins. It, like other bone morphogenetic proteins (BMPs), is involved in the development of bone and cartilage. BMP8A may be involved in epithelial osteogenesis. It also plays a role in bone homeostasis. It is a disulfide-linked homodimer.

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000183682 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000032726 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ "Entrez Gene: bone morphogenetic protein 8a".

External links

[edit]
  • Human BMP8A genome location and BMP8A gene details page in the UCSC Genome Browser.

Further reading

[edit]
  • Davila S, Froeling FE, Tan A, et al. (2010). "New genetic associations detected in a host response study to hepatitis B vaccine". Genes Immun. 11 (3): 232–8. doi:10.1038/gene.2010.1. PMID 20237496. S2CID 11183658.
  • Strausberg RL, Feingold EA, Grouse LH, et al. (2002). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. Bibcode:2002PNAS...9916899M. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
  • Gregory SG, Barlow KF, McLay KE, et al. (2006). "The DNA sequence and biological annotation of human chromosome 1". Nature. 441 (7091): 315–21. Bibcode:2006Natur.441..315G. doi:10.1038/nature04727. PMID 16710414.
  • Ota T, Suzuki Y, Nishikawa T, et al. (2004). "Complete sequencing and characterization of 21,243 full-length human cDNAs". Nat. Genet. 36 (1): 40–5. doi:10.1038/ng1285. PMID 14702039.
  • v
  • t
  • e
Cell signaling: TGFβ signaling pathway
TGF beta superfamily of ligands
Ligand of ACVR or TGFBR
  • TGF beta family
    • TGF-β1
    • TGF-β2
    • TGF-β3
  • Activin and inhibin
    • INHA
    • INHBA
    • INHBB
    • INHBC
  • Nodal
Ligand of BMPR
  • Bone morphogenetic proteins
    • BMP2
    • BMP3
    • BMP4
    • BMP5
    • BMP6
    • BMP7
    • BMP8a
    • BMP8b
    • BMP10
    • BMP15
  • Growth differentiation factors
    • GDF1
    • GDF2
    • GDF3
    • GDF5
    • GDF6
    • GDF7
    • Myostatin/GDF8
    • GDF9
    • GDF10
    • GDF11
    • GDF15
  • Anti-müllerian hormone
TGF beta receptors
(Activin, BMP, family)
TGFBR1:
  • Activin type 1 receptors
    • ACVR1
    • ACVR1B
    • ACVR1C
  • ACVRL1
  • BMPR1
    • BMPR1A
    • BMPR1B
TGFBR2:
  • Activin type 2 receptors
    • ACVR2A
    • ACVR2B
  • AMHR2
  • BMPR2
TGFBR3:
  • Betaglycan
Transducers/SMAD
  • R-SMAD (SMAD1
  • SMAD2
  • SMAD3
  • SMAD5
  • SMAD9)
  • I-SMAD (SMAD6
  • SMAD7)
  • SMAD4
Ligand inhibitors
  • Cerberus
  • Chordin
  • Decorin
  • Follistatin
  • Gremlin
  • Lefty
  • LTBP1
  • Noggin
  • PARN
  • THBS1
Coreceptors
  • BAMBI
  • Cripto
Other
  • SARA
  • v
  • t
  • e
TGFβ receptor superfamily modulators
Type I
ALK1 (ACVRL1)
  • Agonists: Activin (A, B, AB)
  • Avotermin
  • BMP (10)
  • Cetermin
  • GDF (2 (BMP9))
  • TGFβ (1, 2, 3)
  • Antibodies: Ascrinvacumab
  • Kinase inhibitors: K-02288
  • ML-347 (LDN-193719, VU0469381)
  • Decoy receptors: Dalantercept
  • Other inhibitors: Disitertide
ALK2 (ACVR1A)
  • Agonists: Activin (A, B, AB)
  • AMH (MIS)
  • Avotermin
  • BMP (5, 6, 7, 8A, 8B)
  • Eptotermin alfa
  • TGFβ (1, 2, 3)
  • Kinase inhibitors: DMH-1
  • DMH-2
  • Dorsomorphin (BML-275)
  • K-02288
  • ML-347 (LDN-193719, VU0469381)
ALK3 (BMPR1A)
  • Agonists: AMH (MIS)
  • BMP (2, 4, 5, 6, 7, 8A, 8B)
  • Dibotermin alfa
  • Eptotermin alfa
  • Kinase inhibitors: DMH-2
  • Dorsomorphin (BML-275)
  • K-02288
ALK4 (ACVR1B)
  • Agonists: Activin (A, B, AB)
  • GDF (1, 3, 11 (BMP11))
  • Myostatin (GDF8)
  • Nodal
  • Antagonists: Inhibin (A, B)
  • Lefty (1, 2)
  • Kinase inhibitors: A 83-01
  • SB-431542
  • SB-505124
ALK5 (TGFβR1)
  • Agonists: Avotermin
  • GDF (10 (BMP3B), 11 (BMP11))
  • TGFβ (1, 2, 3)
  • Antibodies: Fresolimumab
  • Lerdelimumab
  • Metelimumab
  • Kinase inhibitors: A 83-01
  • D-4476
  • GW-788388
  • LY-364947
  • LY-2109761
  • Galunisertib (LY-2157299)
  • R-268712
  • RepSox (E-616452, SJN-2511)
  • SB-431542
  • SB-505124
  • SB-525334
  • SD-208
ALK6 (BMPR1B)
  • Agonists: BMP (2, 4, 5, 6, 7, 8A, 8B, 15 (GDF9B))
  • Dibotermin alfa
  • Eptotermin alfa
  • GDF (5 (BMP14), 6 (BMP13), 7 (BMP12), 9, 15)
  • Radotermin
  • Kinase inhibitors: DMH-2
  • Dorsomorphin (BML-275)
  • K-02288
ALK7 (ACVR1C)
  • Agonists: GDF (1, 3, 11 (BMP11))
  • Nodal
  • Antagonists: Lefty (1, 2)
  • Kinase inhibitors: A 83-01
  • SB-431542
  • SB-505124
Type II
TGFβR2
  • Agonists: Avotermin
  • GDF (10 (BMP3B))
  • TGFβ (1, 2, 3)
  • Antibodies: Fresolimumab
  • Lerdelimumab
  • Metelimumab
  • Kinase inhibitors: DMH-2
  • LY-364947
BMPR2
  • Agonists: BMP (2, 4, 6, 7, 10)
  • Dibotermin alfa
  • Eptotermin alfa
  • GDF (2 (BMP9), 5 (BMP14), 6 (BMP13), 7 (BMP12))
  • Radotermin
  • Antagonists: Inhibin (A, B)
ACVR2A (ACVR2)
  • Agonists: Activin (A, B, AB)
  • BMP (2, 4, 5, 6, 7, 8A, 8B, 15 (GDF9B))
  • Dibotermin alfa
  • Eptotermin alfa
  • GDF (1, 3, 5 (BMP14), 6 (BMP13), 7 (BMP12), 9, 11 (BMP11), 15)
  • Myostatin (GDF8)
  • Nodal
  • Radotermin
  • Antagonists: Inhibin (A, B)
  • Lefty (1, 2)
  • Decoy receptors: Sotatercept
ACVR2B
  • Agonists: Activin (A, B, AB)
  • BMP (2, 4, 6, 7)
  • Dibotermin alfa
  • Eptotermin alfa
  • GDF (1, 3, 5 (BMP14), 6 (BMP13), 7 (BMP12))
  • Myostatin (GDF8)
  • Nodal
  • Osteogenin (BMP3, BMP3A)
  • Radotermin
  • Antagonists: Inhibin (A, B)
  • Lefty (1, 2)
  • Decoy receptors: Ramatercept
AMHR2 (AMHR)
  • Agonists: AMH (MIS)
Type III
TGFβR3 (β-glycan)
  • Ligands: Avotermin
  • Inhibin (A, B)
  • TGFβ (1, 2, 3)
Unsorted
  • Endogenous antagonists/inhibitors: BAMBI
  • Cerberus (CER1)
  • Chordin
  • DAN (PARN)
  • Decorin
  • Follistatin
  • Gremlin (Drm)
  • LTBP1
  • Noggin
  • TGIF
  • Thrombospondin 1 (THBS1)
  • Tomoregulin 1
  • Antibodies: Stamulumab (against myostatin)
  • TRC105 (against endoglin)
  • Others: Endoglin


Stub icon

This article on a gene on human chromosome 1 is a stub. You can help Wikipedia by adding missing information.

  • v
  • t
  • e
Retrieved from "https://teknopedia.ac.id/w/index.php?title=Bone_morphogenetic_protein_8A&oldid=1301003065"
Categories:
  • Genes on human chromosome 1
  • Bone morphogenetic protein
  • Developmental genes and proteins
  • TGFβ domain
  • Human chromosome 1 gene stubs
Hidden categories:
  • Articles with short description
  • Short description matches Wikidata
  • All stub articles

  • indonesia
  • Polski
  • العربية
  • Deutsch
  • English
  • Español
  • Français
  • Italiano
  • مصرى
  • Nederlands
  • 日本語
  • Português
  • Sinugboanong Binisaya
  • Svenska
  • Українська
  • Tiếng Việt
  • Winaray
  • 中文
  • Русский
Sunting pranala
url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url
Pusat Layanan

UNIVERSITAS TEKNOKRAT INDONESIA | ASEAN's Best Private University
Jl. ZA. Pagar Alam No.9 -11, Labuhan Ratu, Kec. Kedaton, Kota Bandar Lampung, Lampung 35132
Phone: (0721) 702022
Email: pmb@teknokrat.ac.id